Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab (ONO-4538) Expanded Access Program for Epithelial Skin Malignancies
jRCT2031230036Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in cutaneous malignancy, sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability (adverse events). Started Apr 2023; status: completed.
02
Drugs
03
Conditions
cutaneous malignancy
Beyond the preview
Go deeper on jRCT2031230036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230036.